NEW YORK CITY, NY / ACCESS Newswire / April 4, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on ...

Eye health company Bausch & Lomb is recalling some of its intraocular lenses over possible safety concerns. The voluntary ...

Alcon introduced the Clareon PanOptix Pro trifocal IOL, which will be commercially available in the U.S. in May, for patients ...

Q1 2025 Management View CEO Dr. Ron Kurtz highlighted that Q1 2025 revenue was impacted by a weakened premium intraocular lens (IOL) market, disruptions from sequential product launches by competitors ...

Bausch + Lomb shares tumbled in intraday trading Friday, a day after the eye-care company announced a "voluntary recall" of ...

Phakic IOL technologies have undergone substantial improvements in recent years, with progressive upgrades in design and material and more accurate sizing strategies.At the ESCRS winter meeting, Erik ...

RxSight faces revenue decline and rising competition in the IOL market. Click here to find out why I am neutral on RXST stock ...

JP Morgan downgraded RxSight to Underweight, citing market, economic, and competitive headwinds that have led to a weaker-than-expected first-quarter performance and a downward revision to 2025 ...

Eye health company Bausch + Lomb has issued a voluntary recall of a series of intraocular lenses, according to a March 27 ...

Bausch + Lomb has recalled intraocular lenses in response to a growing number of reports that some patients are experiencing inflammatory reactions in their eyes, the company said Thursday.

Bausch + Lomb has recalled its intraocular lenses after receiving reports of cases inflammation. The Canadian eyecare company said Thursday that it has made a voluntary recall of its intraocular ...